The EJP RD brings over 130 institutions (including all 24 ERNs) from 35 countries: 26 EU Member States, 7 associated, UK & Canada. The aim is to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation on rare diseases (RD) research by improving its integration and implementing efficient financial models to support it.
Radboudumc is a full partner of EJP RD project and thus ALL researchers and stakeholders belonging to it can profit from the proposed program and join the meeting.
This year the GA program is going to be very rich and tailored to the specific interests of RD community.
The participants will be joining several workshops focused on:
- improving the understanding of ongoing EJP RD funding mechanisms to increase quality of their applications
- strengthening the capacity building to develop their new findings towards clinical settings
- training them in the use of systems to diagnose difficult RD cases with exome/genome data
- introducing novel and innovative methodologies applied to RD clinical trials
- explaining EJP RD considerations on interoperability to make registry interoperable and FAIR
Special attention will be dedicated to “education” on RD research with two interactive sessions on 1) how to fill the gaps and implement programs for researchers and young clinicians; 2) developing the RD e-learning scheme to align all actions.
Plenary and parallel Pillar sessions will provide inputs that would be used to finalize the EJP RD roadmap for 2021.
Please, have a look to the preliminary program of the meeting (the program will be regularly updated with more details on the content of each sessions, so do not hesitate to visit our site).
Members of all EJP RD participating institutions are invited to register here to take part at the EJP RD GA meeting and receive all necessary information to connect to the sessions.
Recorded webinar(s) will be freely available on the EJP RD website and on its official YouTube channel after the meeting to share good practices, relevant contents, and important support materials with the whole RD community.
Tune with us on twitter at the @EJPRareDiseases account and look at the EJP RD website to get the latest news from the EJP RD community.
Feel free to contact us at the email@example.com if you have any questions.
Related news items
Dutch Cancer Society Grant received by Annemiek van Spriel and Laia Querol-Cano23 September 2020
Annemiek van Spriel and Laia Querol-Cano received a Dutch Cancer Society Grant of 700K euros to study the cancer cell surface in immunotherapy.read more
Tumor cells stimulate lipid biosynthesis in macrophages23 September 2020
RIMLS researchers wrote in the Journal for ImmunoTherapy of Cancer that improved lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics.read more
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genomics of Neurodevelopmental Disorders17 September 2020
Annette Schenck has been appointed professor of Translational Genomics of Neurodevelopmental Disorders. with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more